Cover Image
市場調查報告書

PharmaPoint:潰瘍性大腸炎(UC) - 全球醫藥品的預測與市場分析

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

出版商 GlobalData 商品編碼 299707
出版日期 內容資訊 英文 341 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:潰瘍性大腸炎(UC) - 全球醫藥品的預測與市場分析 PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
出版日期: 2014年09月30日 內容資訊: 英文 341 Pages
簡介

全球主要10個國家的潰瘍性大腸炎(UC)治療藥市場,2012年達到42億美元,預計2022年擴大到約68億美元(其間的年複合成長率(CAGR)為4.9%)。來自大型製藥企業的新治療藥(Johnson & Johnson的Simponi和武田藥品工業的Entyvio等)的上市促進市場成長,另一方面由於專利失效伴隨的生技仿製藥的銷售等,可能妨礙今後的市場成長。

本報告提供全球的潰瘍性大腸炎(UC)的市場現況與未來展望相關分析、疾病概要和今後的流行病學預測、在主要國家的預防體制、主要企業簡介與代表性產品、市場未滿足需求與未來性的機會、現在臨床實驗中的開發中產品的資訊、今後的市場規模及影響要素等調查結果,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理
    • 病因
    • 病理
  • 症狀
    • 生活品質(QoL)

第4章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
    • 白人、猶太人的感染風險高37倍
    • 一級親屬的家族病史:發病風險高3倍
    • 吸煙者的發病風險,比戒煙者、非吸煙者低
  • 全球各國的趨勢
    • 美國
    • 歐洲主要5個國家
    • 日本
    • 加拿大
    • 中國
    • 印度
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 潰瘍性大腸炎(UC)的流行病學預測(今後11年份)
    • 潰瘍性大腸炎的發病率
    • 各年齡的發病率
    • 男女的發病率
    • 已調整年齡的發病率
  • 潰瘍性大腸炎的患病人數的預測(今後11年份)
    • 潰瘍性大腸炎的患病人數
    • 患病人數(各年齡)
    • 患病人數(男女)
    • 年齡已調整的患病人數
  • 議論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷、治療概要
    • 診斷
    • 治療的指南與代表性處方藥
    • 臨床診療
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大
  • 中國
  • 印度

第6章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:領導品牌
    • Remicade (infliximab)
    • Humira (adalimumab)
    • Simponi (golimumab)
    • Entyvio (vedolizumab)
    • Apriso (mesalamine)
    • Asacol HD (mesalamine)
    • Lialda (mesalamine)
    • Pentasa (mesalamine)
    • Colazal (balsazide disodium)
    • Giazo (balsalazide disodium)
    • sfRowasa (mesalamine)
    • Uceris (budesonide)
    • 其他藥劑級
  • 生技仿製藥
    • 序論
    • 對主要的自體免疫疾病的效力:Inflectra (Hospira) vs. Remicade (J&J)
    • 免疫學社群的生技仿製藥
    • 正在開發的生技仿製藥
    • 生技仿製藥對製藥產業全體的影響力
    • 生技仿製藥市場預測

第7章 市場機會及未滿足需求

  • 概要
  • 未滿足需求
    • 生命垂危患者的根治療法
    • 各重症度的診斷標記
    • 個人化醫療
    • 類固醇的替代藥
    • 新的口服藥
    • 降低相關疾病(大腸癌)風險的預防藥
    • 感染疾病的不良事件的管理改善
  • 未滿足需求的差距分析
  • 重病度和大腸癌症生物標記為基礎的預測工具
  • 難治性疾病的徵兆

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
    • 各國臨床實驗製圖
  • 各Phase、各臨床實驗階段臨床實驗進展
  • 臨床實驗中有前途的醫藥品
    • Entyvio (vedolizumab)
    • Xeljanz (tofacitinib)
    • Kappaproct (DIMS 0150)

第9章 現在、未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Johnson & Johnson
    • AbbVie
    • 武田藥品工業
    • Roche
    • Warner Chilcott
    • Salix Pharmaceuticals/Santarus
    • Shire Pharmaceuticals
    • Ferring Pharmaceuticals
    • Pfizer
    • InDeX Pharmaceuticals

第10章 市場預測

  • 全球市場
    • 市場預測
    • 促進、阻礙因素:全球的課題
  • 美國市場
    • 市場預測
    • 近幾年的主要趨勢
    • 市場促進、阻礙因素
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大
  • 中國
  • 印度

第11章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC005EPIDR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market.

Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Overall, major barriers to the growth of the UC market include -

  • Remicade and Humira losing patent protection in the mid-forecast
  • Austerity measures favoring generic prescribing
  • Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US

Highlights

Key Questions Answered

  • How will the UC market (sales and patient numbers) evolve over the 10-year forecast period from 2012 to 2022?
  • How will the launch of the first-in-class Entyvio change the landscape of the UC market?
  • Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
  • How will the launch of late-stage pipeline therapies such as etrolizumab and Kappaproct shape the future treatment landscape?
  • What are the remaining unmet needs and opportunities for drug developers within the UC market?

Key Findings

  • The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade.
  • Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market.
  • During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis.

Scope

  • Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs.
  • Analysis of the current and future market competition in the global UC therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global UC therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global UC therapeutics markets from 2012-2022.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. Being Caucasian and Jewish can increase the risk of UC by almost 37 times
    • 4.2.2. A family history of UC in first-degree relatives can increase the risk of the disease by almost three-fold
    • 4.2.3. Current smokers have a lower risk of developing UC than former smokers or never smokers
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
    • 4.3.4. Canada
    • 4.3.5. China
    • 4.3.6. India
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of UC (2012-2022)
    • 4.5.1. Incident Cases of UC
    • 4.5.2. Age-Specific Incident Cases of UC
    • 4.5.3. Sex-Specific Incident Cases of UC
    • 4.5.4. Age-Standardized Incidence Rates
  • 4.6. Epidemiological Forecast for UC Prevalent Cases (2012-2022)
    • 4.6.1. Prevalent Cases of UC
    • 4.6.2. Age-Specific Prevalent Cases of UC
    • 4.6.3. Sex-Specific Prevalent Cases of UC
    • 4.6.4. Age-Standardized Prevalence Rate of UC in All Markets
  • 4.7. Discussion
    • 4.7.1. Epidemiological Forecast Insight
    • 4.7.2. Limitations of the Analysis
    • 4.7.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Canada
  • 5.10. China
  • 5.11. India

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Remicade (infliximab)
    • 6.3.2. Humira (adalimumab)
    • 6.3.3. Simponi (golimumab)
    • 6.3.4. Entyvio (vedolizumab)
    • 6.3.5. Apriso (mesalamine)
    • 6.3.6. Asacol HD (mesalamine)
    • 6.3.7. Lialda (mesalamine)
    • 6.3.8. Pentasa (mesalamine)
    • 6.3.9. Colazal (balsazide disodium)
    • 6.3.10. Giazo (balsalazide disodium)
    • 6.3.11. sfRowasa (mesalamine)
    • 6.3.12. Uceris (budesonide)
    • 6.3.13. Other Drug Classes Used in the Treatment of UC
  • 6.4. Biosimilars
    • 6.4.1. Introduction
    • 6.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 6.4.3. Biosimilars in the Immunology Community
    • 6.4.4. By the Numbers: Biosimilars in Development
    • 6.4.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 6.4.6. Biosimilars' Forecast

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Unmet Needs
    • 7.2.1. Curative Therapy for Severe UC Patients
    • 7.2.2. Diagnostic Markers for Disease Severity
    • 7.2.3. Personalized Therapy
    • 7.2.4. A Replacement for Steroids
    • 7.2.5. Novel Oral Drug Formulations
    • 7.2.6. Preventative Medicine for Lowering the Associated Colorectal Cancer Risk
    • 7.2.7. Improved Management of Infectious Adverse Events
  • 7.3. Unmet Needs Gap Analysis
  • 7.4. Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools
  • 7.5. Predictors of Medically-Refractory Disease

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising Drugs in Clinical Development
    • 8.4.1. Etrolizumab
    • 8.4.2. Xeljanz (tofacitinib)
    • 8.4.3. Kappaproct (DIMS 0150)

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Johnson & Johnson
    • 9.3.2. AbbVie
    • 9.3.3. Takeda Pharmaceuticals
    • 9.3.4. Roche
    • 9.3.5. Warner Chilcott
    • 9.3.6. Salix Pharmaceuticals/Santarus
    • 9.3.7. Shire Pharmaceuticals
    • 9.3.8. Ferring Pharmaceuticals
    • 9.3.9. Pfizer
    • 9.3.10. InDeX Pharmaceuticals

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Canada
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. China
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers
  • 10.11. India
    • 10.11.1. Forecast
    • 10.11.2. Key Events
    • 10.11.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed UC Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Author
    • 11.7.2. Epidemiologist
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Strongest Putative Risk Factors for UC
  • Table 4: Prevalence of UC in the US
  • Table 5: Incidence of UC in the 5EU
  • Table 6: Prevalence of UC in the 5EU
  • Table 7: 10MM, Sources of UC Incidence Data Used in the Epidemiological Forecast
  • Table 8: 10MM, Sources of UC Prevalence Data Used in the Epidemiological Forecast
  • Table 9: 10MM, Incident Cases of UC, Ages ≥10 Years, Both Sexes, N, Select Years, 2012-2022
  • Table 10: 10MM, Incident Cases of UC, By Age, Both Sexes, N (Row %), 2012
  • Table 11: 10MM, Incident Cases of UC, By Sex, Ages ≥10 Years, N (Row %), 2012
  • Table 12: 10MM, Prevalent Cases of UC, Ages ≥10 Years, Both Sexes, N, Select Years, 2012-2022
  • Table 13: 10MM, Prevalent Cases of UC, By Age, Both Sexes, N (Row %), 2012
  • Table 14: 10MM, Prevalent Cases of UC, By Sex, Ages ≥10 Years, N (Row %), 2012
  • Table 15: Truelove and Witts UC Severity Index
  • Table 16: UCDAI
  • Table 17: Treatment Guidelines for UC Used in the 10MM
  • Table 18: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 19: UC Management Country Profile - US
  • Table 20: UC Management Country Profile - France
  • Table 21: UC Management Country Profile - Germany
  • Table 22: UC Management Country Profile - Italy
  • Table 23: UC Management Country Profile - Spain
  • Table 24: UC Management Country Profile - UK
  • Table 25: UC Management Country Profile - Japan
  • Table 26: Country Profile - Canada
  • Table 27: UC Management Country Profile - China
  • Table 28: UC Management Country Profile - India
  • Table 29: Leading Treatments for UC, 2014
  • Table 30: Product Profile - Remicade
  • Table 31: Remicade SWOT Analysis, 2014
  • Table 32: Global Sales Forecasts ($m) for Remicade, 2012-2022
  • Table 33: Product Profile - Humira
  • Table 34: Humira Efficacy in the ULTRA 2 Trial
  • Table 35: Product Efficacy Comparison - Humira vs. Remicade
  • Table 36: Humira SWOT Analysis, 2014
  • Table 37: Global Sales Forecasts ($m) for Humira, 2012-2022
  • Table 38: Product Profile - Simponi
  • Table 39: Simponi SWOT Analysis, 2014
  • Table 40: Global Sales Forecasts ($m) for Simponi, 2012-2022
  • Table 41: Product Profile - Entyvio
  • Table 42: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC
  • Table 43: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC
  • Table 44: Most Common Adverse Events with Vedolizumab in the GEMINI I Study
  • Table 45: Entyvio SWOT Analysis, 2014
  • Table 46: Global Sales Forecasts ($m) for Entyvio, 2012-2022
  • Table 47: Product Profile - Apriso
  • Table 48: Apriso SWOT Analysis, 2014
  • Table 49: Global Sales Forecasts ($m) for Apriso, 2012-2022
  • Table 50: Product Profile - Asacol HD
  • Table 51: Asacol HD SWOT Analysis, 2014
  • Table 52: Global Sales Forecasts ($m) for Asacol HD, 2012-2022
  • Table 53: Product Profile - Lialda
  • Table 54: Lialda SWOT Analysis, 2014
  • Table 55: Global Sales Forecasts ($m) for Lialda, 2012-2022
  • Table 56: Product Profile - Pentasa
  • Table 57: Pentasa SWOT Analysis, 2014
  • Table 58: Global Sales Forecasts ($m) for Pentasa, 2012-2022
  • Table 59: Product Profile - Colazal
  • Table 60: Colazal SWOT Analysis, 2014
  • Table 61: Global Sales Forecasts ($m) for Colazal, 2012-2022
  • Table 62: Product Profile - Giazo
  • Table 63: Giazo SWOT Analysis, 2014
  • Table 64: Global Sales Forecasts ($m) for Giazo, 2012-2022
  • Table 65: Product Profile - sfRowasa
  • Table 66: sfRowasa SWOT Analysis, 2014
  • Table 67: Global Sales Forecasts ($m) for sfRowasa, 2012-2022
  • Table 68: Product Profile - Uceris
  • Table 69: Uceris SWOT Analysis, 2014
  • Table 70: Global Sales Forecasts ($m) for Uceris, 2012-2022
  • Table 71: Summary of Other Immunomodulators for UC, 2013
  • Table 72: Biosimilars Pipeline, 2014
  • Table 73: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2012-2022
  • Table 74: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2012-2022
  • Table 75: Global Sales Forecasts ($m) for Golimumab Biosimilars, 2012-2022
  • Table 76: Overall Unmet Needs - Current Level of Attainment
  • Table 77: Corticosteroid Long-Term Side Effects
  • Table 78: Clinical Unmet Needs in UC - Gap Analysis, 2013
  • Table 79: Prognostic Markers in UC
  • Table 80: UC - Clinical Trials by Phase and Status, 2014
  • Table 81: UC - Pre-Registration and Phase III Pipeline, 2014
  • Table 82: Comparison of Therapeutic Classes in Development for UC, 2014
  • Table 83: Product Profile - Etrolizumab
  • Table 84: Results of Phase IIa Trial of Etrolizumab in the Induction of Remission in UC
  • Table 85: Most Common Adverse Events in the Phase IIa Trial of etrolizumab
  • Table 86: Etrolizumab SWOT Analysis, 2014
  • Table 87: Global Sales Forecasts ($m) for Etrolizumab, 2012-2022
  • Table 88: Product Profile - Xeljanz
  • Table 89: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC
  • Table 90: Most Common Adverse Events in the Phase IIa Trial of Xeljanz
  • Table 91: Xeljanz SWOT Analysis, 2014
  • Table 92: Global Sales Forecasts ($m) for Xeljanz, 2012-2022
  • Table 93: Product Profile - Kappaproct
  • Table 94: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC
  • Table 95: Kappaproct SWOT Analysis, 2014
  • Table 96: Global Sales Forecasts ($m) for Kappaproct, 2012-2022
  • Table 97: Key Companies in the UC Market, 2012-2022
  • Table 98: J&J's UC Portfolio Assessment, 2014
  • Table 99: J&J's SWOT Analysis in UC, 2014
  • Table 100: AbbVie's UC Portfolio Assessment, 2014
  • Table 101: AbbVie's UC SWOT Analysis, 2014
  • Table 102: Takeda Pharmaceuticals' UC Portfolio Assessment, 2014
  • Table 103: Takeda's UC SWOT Analysis, 2014
  • Table 104: Roche's UC Portfolio Assessment, 2014
  • Table 105: Roche's UC SWOT Analysis, 2014
  • Table 106: Warner Chilcott's UC Portfolio Assessment, 2014
  • Table 107: Warner Chilcott's UC SWOT Analysis, 2014
  • Table 108: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013
  • Table 109: Salix Pharmaceuticals/Santarus UC SWOT Analysis, 2014
  • Table 110: Shire Pharmaceuticals' UC Portfolio Assessment, 2014
  • Table 111: Shire Pharmaceuticals' UC SWOT Analysis, 2014
  • Table 112: Ferring Pharmaceuticals' UC Portfolio Assessment, 2013
  • Table 113: Ferring Pharmaceutical's UC SWOT Analysis, 2014
  • Table 114: Pfizer's UC Portfolio Assessment, 2014
  • Table 115: Pfizer's UC SWOT Analysis, 2014
  • Table 116: InDeX Pharmaceuticals' UC Portfolio Assessment, 2013
  • Table 117: InDeX Pharmaceuticals' UC SWOT Analysis, 2014
  • Table 118: Global Sales Forecasts ($m) for UC, 2012-2022
  • Table 119: Global UC Market - Drivers and Barriers, 2012-2022
  • Table 120: Sales Forecasts ($m) for UC in the US, 2012-2022
  • Table 121: Key Events Impacting Sales for UC in the US, 2012-2022
  • Table 122: UC Market in the US - Drivers and Barriers, 2012-2022
  • Table 123: Sales Forecasts ($m) for UC in France, 2012-2022
  • Table 124: Key Events Impacting Sales for UC in France, 2012-2022
  • Table 125: UC Market in France - Drivers and Barriers, 2012-2022
  • Table 126: Sales Forecasts ($m) for UC in Germany, 2012-2022
  • Table 127: Key Events Impacting Sales for UC in Germany, 2012-2022
  • Table 128: UC Market in Germany - Drivers and Barriers, 2012-2022
  • Table 129: Sales Forecasts ($) for UC in Italy, 2012-2022
  • Table 130: Key Events Impacting Sales for UC in Italy, 2012-2022
  • Table 131: UC Market in Italy - Drivers and Barriers, 2012-2022
  • Table 132: Sales Forecasts ($m) for UC in Spain, 2012-2022
  • Table 133: Key Events Impacting Sales for UC in Spain, 2012-2022
  • Table 134: UC Market in Spain - Drivers and Barriers, 2012-2022
  • Table 135: Sales Forecasts ($m) for UC in the UK, 2012-2022
  • Table 136: Key Events Impacting Sales for UC in the UK, 2012-2022
  • Table 137: UC Market in the UK - Drivers and Barriers, 2012-2022
  • Table 138: Sales Forecasts ($) for UC in Japan, 2012-2022
  • Table 139: Key Events Impacting Sales for UC in Japan, 2012-2022
  • Table 140: UC Market in Japan - Drivers and Barriers, 2012-2022
  • Table 141: Sales Forecasts ($m) for UC in Canada, 2012-2022
  • Table 142: Key Events Impacting Sales for UC in Canada, 2012-2022
  • Table 143: UC Market in Canada - Drivers and Barriers, 2012-2022
  • Table 144: Sales Forecasts ($) for UC in China, 2012-2022
  • Table 145: Key Events Impacting Sales for UC in China, 2012-2022
  • Table 146: UC Market in China - Drivers and Barriers, 2012-2022
  • Table 147: Sales Forecasts ($) for UC in India, 2012-2022
  • Table 148: Key Events Impacting Sales for UC in India, 2012-2022
  • Table 149: UC Market in India - Drivers and Barriers, 2012-2022
  • Table 150: Key launches for Ulcerative Colitis , 2012-2022
  • Table 151: Key Patent Expiries
  • Table 152: Annual Cost of Therapy for 5-ASAs ($)
  • Table 153: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: Olmsted Country, Minnesota, US, Age- and Sex-Adjusted Incidence of UC, Cases per 100,000 Population, 1940-2000
  • Figure 3: Canada, Incidence and Prevalence of UC, Cases per 100,000 Population, 1990-2001
  • Figure 4: Hong Kong, China, Crude Incidence and Prevalence of UC, Cases per 100,000 Population, 1997-2006
  • Figure 5: 10MM, Incident Cases of UC, Ages ≥ 10 Years, Both Sexes, N, 2012-2022
  • Figure 6: 10MM, Incident Cases of UC, By Age, Both Sexes, N, 2012
  • Figure 7: 10MM, Incident Cases of UC, By Sex, Ages ≥10 Years, N, 2012
  • Figure 8: 10MM, Age-Standardized Incidence of UC, Ages ≥10 Years, Both Sexes, Cases per 100,000 Population, 2012
  • Figure 9: 10MM, Prevalent Cases of UC, Ages ≥10 Years, Both Sexes, N, 2012-2022
  • Figure 10: 10MM, Prevalent Cases of UC, By Sex, Ages ≥ 10 Years, N, 2012
  • Figure 11: 10MM, Prevalent Cases of UC, By Sex, Ages ≥10 Years, N, 2012
  • Figure 12: 10MM, Age-Standardized Prevalence of UC, Ages ≥10 Years, Both Sexes, %, 2012
  • Figure 13: UC Disease Management Flowchart
  • Figure 14: UC Therapeutics - Clinical Trials by Country, 2014
  • Figure 15: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022
  • Figure 16: Company Portfolio Gap Analysis in UC, 2012-2022
  • Figure 17: Global Sales ($m) for UC by Region, 2012-2022
  • Figure 18: Sales for UC in the US by Drug Class, 2012-2022
  • Figure 19: Sales for UC in France by Drug Class, 2012-2022
  • Figure 20: Sales for UC in Germany by Drug Class, 2012-2022
  • Figure 21: Sales for UC in Italy by Drug Class, 2012-2022
  • Figure 22: Sales for UC in Spain by Drug Class, 2012-2022
  • Figure 23: Sales for UC in the UK by Drug Class, 2012-2022
  • Figure 24: Sales for UC in Japan by Drug Class, 2012-2022
  • Figure 25: Sales for UC in Canada by Drug Class, 2012-2022
  • Figure 26: Sales for UC in China by Drug Class, 2012-2022
  • Figure 27: Sales for UC in India by Drug Class, 2012-2022
Back to Top